Agency: Cordis | Branch: FP7 | Program: CP | Phase: ICT-2011.5.1 | Award Amount: 4.30M | Year: 2011
Epilepsy, the propensity for recurrent, unprovoked epileptic seizures, is the most common serious neurological disorder, affecting over 50 million people worldwide. Epileptic seizures manifest with a wide variety of motor, cognitive, affective, and autonomic symptoms and signs and associated changes in the electrical activities of the brain (EEG), heart (ECG), muscles (EMG), skin (GSR), as well as changes in other important measurable biological parameters, such as respiration and blood pressure. Their recognition and full understanding is the basis for their optimal management and treatment, but presently is unsatisfactory in many respects. Epileptic seizures occur unpredictably and typically outside hospital and are often misdiagnosed as other episodic disturbances such as syncope, psychogenic and sleep disorders, with which they may co-exist, blurring the clinical presentation; on the other hand, costs of hospital evaluation are substantial, frequently without the desirable results, due to suboptimal monitoring capabilities. \nReliable diagnosis requires state of the art monitoring and communication technologies providing real-time, accurate and continuous brain and body multi-parametric data measurements, suited to the patients medical condition and normal environment and facing issues of patient and data security, integrity and privacy. \nIn this project we will manage and analyse a large number of already acquired and new multimodal and advanced technology data from brain and body activities of epileptic patients and controls (MEG, multichannel EEG, video, ECG, GSR, EMG, etc) aiming to design ARMOR, a more holistic, personalized, medically efficient and economical monitoring system.\nNew methods and tools will be developed for multimodal data pre-processing and fusion of information from various sources. Novel approaches for large scale analysis (both real-time and offline) of multi-parametric streaming and archived data will be introduced to discover patterns and associations between external indicators and mental states, detect correlations among parallel observations, and identify vital signs changing significantly. Moreover methods for automatically summarizing results and efficiently managing medical data will be developed. ARMOR will incorporate models derived from data analysis based on already existing communication platform solutions emphasising on security and ethical issues and performing required adaptations to meet specifications. Special effort will be devoted in areas such as data anonymization and provision of required service.\nARMOR will provide flexible monitoring optimized for each patient and will be tested in several case studies and evaluated as a wide use ambulatory monitoring tool for seizures efficient diagnosis and management including possibilities for detecting premonitory signs and feedback to the patient.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: HCO-06-2015 | Award Amount: 2.98M | Year: 2015
Smoking is the largest avoidable cause of preventable morbidity worldwide. It causes most of the cases of lung cancer and chronic obstructive pulmonary disease (COPD) and contributes to the development of other lung diseases. The control of smoking is considered as a highly important intervention for the prevention of lung diseases. Tobacco consumption is highly influenced by socioeconomic factors. SmokeFreeBrain aims to address the effectiveness of a multi-level variety of interventions aiming at smoking cessation in high risk target groups within High Middle Income Countries (HMIC) such as unemployed young adults, COPD and asthma patients, as well as within the general population in Low Middle Income Countries (LMIC). The project addresses existing approaches aiming to prevent lung diseases caused by tobacco while at the same time it develops new treatments and analyzes their contextual adaptability to the local and global health care system. SmokeFreeBrain follows an interdisciplinary approach exploiting consortiums expertise in various relevant fields in order to generate new knowledge. State of the art techniques in toxicology, pulmonary medicine, neuroscience and behavior will be utilized to evaluate the effectiveness of: (i) Public Service Announcement (PSA) against smoking, (ii) the use of electronic cigarettes with and without nicotine as a harm reduction approach and/or cessation aid, (iii) a specifically developed neurofeedback intervention protocol against smoking addiction, (iv) a specifically developed intervention protocol based on behavioral therapy, social media/mobile apps and short text messages (sms) and (v) pharmacologic interventions. The main objective of the project is to evaluate the interventions in terms of health economics, by studying their cost-effectiveness, and proposing a scalable plan and a clear pathway to embedding the proposed interventions into policy and practice both in LMIC as well as in HMIC.